Andrew Sinclair - Aug 21, 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role
Director
Signature
/s/ Nick Harvey, Attorney-in-Fact
Stock symbol
ACET
Transactions as of
Aug 21, 2024
Transactions value $
$0
Form type
4
Date filed
8/23/2024, 04:08 PM
Previous filing
Jun 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -28.8K -100% $0.00 0 Aug 21, 2024 Common Stock 28.8K $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +28.8K $0.00 28.8K Aug 21, 2024 Common Stock 28.8K $15.75 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -18.5K -100% $0.00 0 Aug 21, 2024 Common Stock 18.5K $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +18.5K $0.00 18.5K Aug 21, 2024 Common Stock 18.5K $15.93 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -8.17K -100% $0.00 0 Aug 21, 2024 Common Stock 8.17K $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +8.17K $0.00 8.17K Aug 21, 2024 Common Stock 8.17K $15.93 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -18.5K -100% $0.00 0 Aug 21, 2024 Common Stock 18.5K $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +18.5K $0.00 18.5K Aug 21, 2024 Common Stock 18.5K $11.49 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -26.4K -100% $0.00 0 Aug 21, 2024 Common Stock 26.4K $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +26.4K $0.00 26.4K Aug 21, 2024 Common Stock 26.4K $5.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 The shares subject to this option are fully vested and exercisable as of the date hereof.